

External Quality Assessment Scheme

## ***Trichomonas vaginalis*, detection** **Round 1, 2023**

### **Specimens**

Please find enclosed 3 artificial vaginal discharge liquid samples S001, S002 and S003, each 1 mL.

### **Caution**

The samples are inactivated and should contain no infectious material. However, they should be handled with the same care as normal patient samples, capable of transmitting infectious disease.

### **Examinations**

*Trichomonas vaginalis*, antigen detection

*Trichomonas vaginalis*, nucleic acid detection

### **Storage and use**

After arrival, the samples should be stored at +2...8 °C.

1. The samples are ready for use.
2. Let the samples warm up to room temperature and mix well.
  - Put a sample collection swab into the sample tube, mix and let it absorb for 10 seconds.
  - If the samples should be diluted use the sample diluent supplied by your test kit. Use the same dilution ratio as instructed in your test kit's instructions.
3. Prepare and test the samples similar to patient samples according to the instructions of your test kit.

### **Result reporting**

Please enter the results and methods via LabScala (www.labscala.com). If you cannot find your instrument or reagent from the registry, please contact the EQA Coordinator. Report only the results of examinations that are in use in your laboratory. All reported examinations will be scored.

S001



S002



S003



2023-01-31

### **INSTRUCTIONS**

Product no. 5473

LQ769923011-013/CA

If the kit is incomplete or contains damaged specimens, please report immediately to [info@labquality.fi](mailto:info@labquality.fi).

---

The results should be reported no later than **February 28, 2023.**

---

The expected results of the round are published in LabScala in the View Reports section by March 3, 2023.

### **Inquiries**

EQA Coordinator

Elina Tuovinen

[elina.tuovinen@labquality.fi](mailto:elina.tuovinen@labquality.fi)

### **Labquality Oy**

Kumpulantie 15

FI-00520 HELSINKI

Finland

Tel. + 358 9 8566 8200

Fax + 358 9 8566 8280

[info@labquality.fi](mailto:info@labquality.fi)


[www.labquality.com](http://www.labquality.com)



Client report

	No of participants	No of responded participants	Response percentage
Trichomonas vaginalis, detection, February, 1-2023	32	31	96.9 %

Summary




Summary	Own score	Max score	Own success rate	Difference	AVR success rate
Specimen S001	2	2	100 %	0 %	100 %
Specimen S002	2	2	100 %	0 %	100 %
Specimen S003	2	2	100 %	0 %	100 %
Average:			100 %	0 %	100 %

History	Test nr.	Own success rate	Difference	AVR success rate
Round 2022-2	1-1	100 %	1.1 %	98.9 %
Round 2022-1	1-1	100 %	0 %	100 %
Round 2021-2	1-1	100 %	1.1 %	98.9 %
Round 2021-1	1-1	100 %	1 %	99 %
Round 2020-2	1-1	100 %	0 %	100 %
Round 2020-1	1-1	100 %	2.3 %	97.7 %
Round 2019-2	1-1	100 %	0 %	100 %
Round 2019-1	1-1	100 %	0 %	100 %


Specimen S001

Specimen S001 success rate




Specimen S001 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Trichomonas vaginalis NAT	2	2	100 %	0 %	100 %	28
	Trichomonas vaginalis Ag	-	-	-	-	100 %	3
	Further action	-	-	-	-	-	3
	Total:	2	2	100 %	0 %	100 %	34

Specimen S001 Trichomonas vaginalis NAT



Specimen S001 Trichomonas vaginalis Ag



OWN DEVICE: AUPAN1

Trichomonas vaginalis NAT	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Positive		27		2	2	100 %	0 %	100 %
		Abbott Alinity m STI Assay		1					
		Becton Dickinson BD Max CT/GC/TV		8					
		Becton Dickinson BD Max Vaginal Panel		1					
		Becton Dickinson BD ProbeTec TV		1					
		Cepheid Xpert TV		5					
		Diagenode Diagnostics S-Dia MGTV		1					
		ELITechGroup STI PLUS ELITe MGP Kit		3					
		<input checked="" type="radio"/> Hologic Aptima Trichomonas vaginalis assay		1					
		In house Trichomonas vaginalis		1					
		Seegene Allplex STI Essential Assay		2					
		Seegene Anyplex II STI-7 Detection		3					
	Weak positive		1		-				100 %
		Seegene Allplex STI Essential Assay		1					
	Total:		28		2	2	100 %	0 %	100 %


Trichomonas vaginalis Ag	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate

	Positive		3		-				100 %
		Nal von minden NADAL Trichomonas vaginalis test		1					
		Sekisui OSOM Trichomonas Rapid Test		2					
	Total:		3		-	-	-	-	100 %

Further action	Response	Response count
	T. vaginalis would be confirmed	3
	Total:	3


Specimen S002

Specimen S002 success rate




Specimen S002 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Trichomonas vaginalis NAT	2	2	100 %	0 %	100 %	28
	Trichomonas vaginalis Ag	-	-	-	-	100 %	3
Total:		2	2	100 %	0 %	100 %	31

Specimen S002 Trichomonas vaginalis NAT



Specimen S002 Trichomonas vaginalis Ag



OWN DEVICE: AUPAN1


Trichomonas vaginalis NAT	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Negative		27		2	2	100 %	0 %	100 %
		Abbott Alinity m STI Assay		1					
		Becton Dickinson BD Max CT/GC/TV		8					
		Becton Dickinson BD Max Vaginal Panel		1					
		Becton Dickinson BD ProbeTec TV		1					
		Cepheid Xpert TV		4					
		Diagenode Diagnostics S-Dia MGTV		1					
		ELITechGroup STI PLUS ELITe MGP Kit		3					
		<input checked="" type="radio"/> Hologic Aptima Trichomonas vaginalis assay		1					
		In house Trichomonas vaginalis		1					
		Seegene Allplex STI Essential Assay		3					
		Seegene Anyplex II STI-7 Detection		3					
	No test result		1		-				-
		Cepheid Xpert TV		1					
Total:			28		2	2	100 %	0 %	100 %

Trichomonas vaginalis Ag	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		3		-				100 %
		Nal von minden NADAL Trichomonas vaginalis test		1					

		Sekisui OSOM Trichomonas Rapid Test		2					
	Total:		3		-	-	-	-	100 %


Specimen S003

Specimen S003 success rate




Specimen S003 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Trichomonas vaginalis NAT	2	2	100 %	0 %	100 %	28
	Trichomonas vaginalis Ag	-	-	-	-	100 %	3
Total:		2	2	100 %	0 %	100 %	31

Specimen S003 Trichomonas vaginalis NAT



Specimen S003 Trichomonas vaginalis Ag



OWN DEVICE: AUPAN1

Trichomonas vaginalis NAT	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Invalid/unclear test result		1		-				-
		Cepheid Xpert TV		1					
	<input checked="" type="radio"/> Negative		26		2	2	100 %	0 %	100 %
		Abbott Alinity m STI Assay		1					
		Becton Dickinson BD Max CT/GC/TV		8					
		Becton Dickinson BD Max Vaginal Panel		1					
		Becton Dickinson BD ProbeTec TV		1					
		Cepheid Xpert TV		3					
		Diagenode Diagnostics S-Dia MGTV		1					
		ELITechGroup STI PLUS ELITe MGP Kit		3					
		<input checked="" type="radio"/> Hologic Aptima Trichomonas vaginalis assay		1					
		In house Trichomonas vaginalis		1					
		Seegene Allplex STI Essential Assay		3					
		Seegene Anyplex II STI-7 Detection		3					
	No test result		1		-				-
		Cepheid Xpert TV		1					
Total:			28		2	2	100 %	0 %	100 %

Trichomonas vaginalis Ag	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		3		-				100 %

		Nal von minden NADAL Trichomonas vaginalis test		1					
		Sekisui OSOM Trichomonas Rapid Test		2					
	Total:		3		-	-	-	-	100 %



**Report Info****PARTICIPANTS**

Altogether 32 laboratories from 9 countries participated in this EQA round.

**REPORT INFO**

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button . In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available".

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

**SCORING**

The round is scored based on test results when 60% or more of the participants report the expected result and when at least three results are reported. The following general rules are applied:

Correct/expected test result 2/2 points  
False/deviating test result 0/2 points


The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores\*100). The Laboratory's Own success rate is the average of the sample success rates.

The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores\*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.

GLOBAL REPORT

	No of participants	No of responded participants	Response percentage
Trichomonas vaginalis, detection, February, 1-2023	32	31	96.9 %


Summary



Summary	AVR success rate
Specimen S001	100 %
Specimen S002	100 %
Specimen S003	100 %
Average:	100 %


Specimen S001

Specimen S001 success rate




Specimen S001 results	Responded	AVR success rate	Count
	Trichomonas vaginalis NAT	100 %	28
	Trichomonas vaginalis Ag	100 %	3
	Further action	-	3
	Total:	100 %	34

Specimen S001 Trichomonas vaginalis NAT



Specimen S001 Trichomonas vaginalis Ag




Trichomonas vaginalis NAT	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Positive		27		100 %	2
		Abbott Alinity m STI Assay		1		
		Becton Dickinson BD Max CT/GC/TV		8		
		Becton Dickinson BD Max Vaginal Panel		1		
		Becton Dickinson BD ProbeTec TV		1		
		Cepheid Xpert TV		5		
		Diagenode Diagnostics S-Dia MGTV		1		
		ELITechGroup STI PLUS ELITe MGP Kit		3		
		Hologic Aptima Trichomonas vaginalis assay		1		
		In house Trichomonas vaginalis		1		
		Seegene Allplex STI Essential Assay		2		
		Seegene Anyplex II STI-7 Detection		3		
	Weak positive		1		100 %	2
		Seegene Allplex STI Essential Assay		1		
	Total:		28		100 %	

Trichomonas vaginalis Ag	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Positive		3		100 %	2
		Nal von minden NADAL Trichomonas vaginalis test		1		
		Sekisui OSOM Trichomonas Rapid Test		2		
	Total:		3		100 %	

Further action	Response	Response count
	T. vaginalis would be confirmed	3
	Total:	3


Specimen S002

Specimen S002 success rate




Specimen S002 results	Responded	AVR success rate	Count
	Trichomonas vaginalis NAT	100 %	28
	Trichomonas vaginalis Ag	100 %	3
	Total:	100 %	31

Specimen S002 Trichomonas vaginalis NAT



Specimen S002 Trichomonas vaginalis Ag




Trichomonas vaginalis NAT	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		27		100 %	2
		Abbott Alinity m STI Assay		1		
		Becton Dickinson BD Max CT/GC/TV		8		
		Becton Dickinson BD Max Vaginal Panel		1		
		Becton Dickinson BD ProbeTec TV		1		
		Cepheid Xpert TV		4		
		Diagenode Diagnostics S-Dia MGTV		1		
		ELITechGroup STI PLUS ELITe MGP Kit		3		
		Hologic Aptima Trichomonas vaginalis assay		1		
		In house Trichomonas vaginalis		1		
		Seegene Allplex STI Essential Assay		3		
		Seegene Anyplex II STI-7 Detection		3		
	No test result		1		-	-
		Cepheid Xpert TV		1		
	Total:		28		100 %	

Trichomonas vaginalis Ag	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		3		100 %	2
		Nal von minden NADAL Trichomonas vaginalis test		1		
		Sekisui OSOM Trichomonas Rapid Test		2		
	Total:		3		100 %	


Specimen S003

Specimen S003 success rate




Specimen S003 results	Responded	AVR success rate	Count
	Trichomonas vaginalis NAT	100 %	28
	Trichomonas vaginalis Ag	100 %	3
	Total:	100 %	31

Specimen S003 Trichomonas vaginalis NAT



Specimen S003 Trichomonas vaginalis Ag



Trichomonas vaginalis NAT	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Invalid/unclear test result		1		-	-
		Cepheid Xpert TV		1		
	Negative		26		100 %	2
		Abbott Alinity m STI Assay		1		
		Becton Dickinson BD Max CT/GC/TV		8		
		Becton Dickinson BD Max Vaginal Panel		1		
		Becton Dickinson BD ProbeTec TV		1		
		Cepheid Xpert TV		3		
		Diagenode Diagnostics S-Dia MGTV		1		
		ELITechGroup STI PLUS ELITe MGP Kit		3		
		Hologic Aptima Trichomonas vaginalis assay		1		
		In house Trichomonas vaginalis		1		
		Seegene Allplex STI Essential Assay		3		
		Seegene Anyplex II STI-7 Detection		3		
	No test result		1		-	-
		Cepheid Xpert TV		1		
	Total:		28		100 %	

Trichomonas vaginalis Ag	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		3		100 %	2
		Nal von minden NADAL Trichomonas vaginalis test		1		
		Sekisui OSOM Trichomonas Rapid Test		2		
	Total:		3		100 %	

**Report Info****PARTICIPANTS**

Altogether 32 laboratories from 9 countries participated in this EQA round.

**REPORT INFO**

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button . In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available".

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

**SCORING**

The round is scored based on test results when 60% or more of the participants report the expected result and when at least three results are reported. The following general rules are applied:

Correct/expected test result 2/2 points  
False/deviating test result 0/2 points

The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores\*100). The Laboratory's Own success rate is the average of the sample success rates.

The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores\*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.

External Quality Assessment Scheme

## ***Trichomonas vaginalis*, detection** **Round 1, 2023**

### **Specimens**

Samples of this EQA round were artificial vaginal discharge liquid samples. Based on the quality controls conducted by the sample material manufacturer and the results obtained in the round, the sample lots are to be considered as homogeneous, stable and suitable for external quality assessment. The materials were sent without temperature control packaging.

The expected results were as follows:

Sample S001 (LQ769923011)  
*Trichomonas vaginalis*, antigen Positive  
*Trichomonas vaginalis*, nucleic acid Positive

Sample S002 (LQ769923012)  
*Trichomonas vaginalis*, antigen Negative  
*Trichomonas vaginalis*, nucleic acid Negative

Sample S003 (LQ769923013)  
*Trichomonas vaginalis*, antigen Negative  
*Trichomonas vaginalis*, nucleic acid Negative

### **Report info**

Please see the description of the data analysis on the last page of the laboratory-specific reports and global reports. It is important to read the Final report first, because it contains important information of the samples and results in each round.

### **Comments – EQA Coordinator**

In this round there were one positive and two negative *T. vaginalis* samples. Overall, the results of the round were good. All participants reported the sample S001 correctly as *T. vaginalis* positive. Also, no false positive results were reported for the negative samples S002 and S003. However, few unexpected “no result” responses were reported from the negative samples. The samples contained human DNA, but the results could indicate that its concentration might not have been sufficient.

### **Exceptions in scoring**

“No test result” as well as “invalid test result”, reported from the negative samples (S002 and S003) were excluded from the scoring, because the concentration of human cells was possibly too low for some methods.

### **End of report**

2023-03-08

### **FINAL REPORT**

Product no. 5473

Samples sent	2023-01-31
Round closed	2023-02-28
Expected results	2023-03-03
Final report	2023-03-08

### **Request for correction**

Typing errors in laboratory's result forms are on laboratory's responsibility. Labquality accepts responsibility only for result processing. Requests must be notified by writing within three weeks from the date of this letter.

### **Authorized by**

EQA Coordinator  
Elina Tuovinen  
elina.tuovinen@labquality.fi

### **Expert**

PhD, Microbiologist, Taru Meri  
University of Helsinki and  
Vita Laboratories, Helsinki, Finland

### **Labquality Oy**

Kumpulantie 15  
FI-00520 HELSINKI  
Finland

Tel. + 358 9 8566 8200  
Fax + 358 9 8566 8280

info@labquality.fi  
www.labquality.com

